"Novo beat its own expectations in the first quarter of the year, reporting a 32% pop in sales on a constant currency basis and a 65% boost in operating profit."
"It's having not cannibalizations, but a synergetic effect."
Novo Nordisk's Wegovy pill has achieved 1.3 million prescriptions in the U.S. during the first quarter of 2026, prompting the company to raise its financial guidance. The CEO noted strong performance and growth in international operations. Despite a modest decline in adjusted sales and operating profit, the results exceeded expectations. Novo forecasts adjusted sales and profit declines of 4 to 12% for the year, an improvement from previous projections. The company believes the pill will attract new users without cannibalizing the injectable version.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]